Becton Dickinson Net Profit Margin 2010-2023 | BDX
Current and historical net profit margin for Becton Dickinson (BDX) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. Becton Dickinson net profit margin for the three months ending December 31, 2023 was .
| Becton Dickinson Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2023-12-31 |
$19.49B |
$1.22B |
6.25% |
| 2023-09-30 |
$19.37B |
$1.42B |
7.35% |
| 2023-06-30 |
$19.05B |
$1.58B |
8.30% |
| 2023-03-31 |
$18.81B |
$1.53B |
8.12% |
| 2022-12-31 |
$18.74B |
$1.52B |
8.11% |
| 2022-09-30 |
$18.87B |
$1.69B |
8.95% |
| 2022-06-30 |
$18.41B |
$1.67B |
9.05% |
| 2022-03-31 |
$18.38B |
$1.83B |
9.96% |
| 2021-12-31 |
$18.53B |
$1.68B |
9.04% |
| 2021-09-30 |
$19.13B |
$2.00B |
10.46% |
| 2021-06-30 |
$18.57B |
$1.87B |
10.04% |
| 2021-03-31 |
$17.82B |
$1.64B |
9.20% |
| 2020-12-31 |
$17.16B |
$1.51B |
8.79% |
| 2020-09-30 |
$16.07B |
$0.77B |
4.77% |
| 2020-06-30 |
$16.92B |
$0.79B |
4.65% |
| 2020-03-31 |
$17.41B |
$0.92B |
5.30% |
| 2019-12-31 |
$17.36B |
$0.76B |
4.38% |
| 2019-09-30 |
$17.29B |
$1.08B |
6.26% |
| 2019-06-30 |
$17.11B |
$0.78B |
4.58% |
| 2019-03-31 |
$17.04B |
$0.93B |
5.44% |
| 2018-12-31 |
$17.06B |
$0.90B |
5.25% |
| 2018-09-30 |
$15.98B |
$0.16B |
0.99% |
| 2018-06-30 |
$14.75B |
$0.62B |
4.21% |
| 2018-03-31 |
$13.50B |
$-0.10B |
-0.74% |
| 2017-12-31 |
$12.25B |
$0.29B |
2.40% |
| 2017-09-30 |
$12.09B |
$1.03B |
8.52% |
| 2017-06-30 |
$12.16B |
$0.76B |
6.25% |
| 2017-03-31 |
$12.32B |
$1.32B |
10.67% |
| 2016-12-31 |
$12.42B |
$1.31B |
10.54% |
| 2016-09-30 |
$12.48B |
$0.98B |
7.82% |
| 2016-06-30 |
$12.31B |
$1.14B |
9.24% |
| 2016-03-31 |
$12.23B |
$0.81B |
6.62% |
| 2015-12-31 |
$11.22B |
$0.69B |
6.13% |
| 2015-09-30 |
$10.28B |
$0.70B |
6.76% |
| 2015-06-30 |
$9.42B |
$0.82B |
8.65% |
| 2015-03-31 |
$8.46B |
$1.08B |
12.75% |
| 2014-12-31 |
$8.48B |
$1.15B |
13.56% |
| 2014-09-30 |
$8.45B |
$1.19B |
14.03% |
| 2014-06-30 |
$8.35B |
$0.97B |
11.67% |
| 2014-03-31 |
$8.24B |
$0.95B |
11.53% |
| 2013-12-31 |
$8.17B |
$0.94B |
11.49% |
| 2013-09-30 |
$8.05B |
$1.29B |
16.05% |
| 2013-06-30 |
$7.92B |
$1.49B |
18.84% |
| 2013-03-31 |
$7.85B |
$1.52B |
19.33% |
| 2012-12-31 |
$7.78B |
$1.53B |
19.70% |
| 2012-09-30 |
$7.71B |
$1.17B |
15.18% |
| 2012-06-30 |
$7.61B |
$1.18B |
15.52% |
| 2012-03-31 |
$7.58B |
$1.20B |
15.79% |
| 2011-12-31 |
$7.57B |
$1.22B |
16.08% |
| 2011-09-30 |
$7.58B |
$1.27B |
16.76% |
| 2011-06-30 |
$7.34B |
$1.37B |
18.64% |
| 2011-03-31 |
$7.22B |
$1.33B |
18.45% |
| 2010-12-31 |
$7.10B |
$1.32B |
18.57% |
| 2010-09-30 |
$7.12B |
$1.32B |
18.50% |
| 2010-06-30 |
$7.22B |
$1.24B |
17.14% |
| 2010-03-31 |
$7.21B |
$1.27B |
17.64% |
| 2009-12-31 |
$7.14B |
$1.24B |
17.30% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$67.707B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
